Siemens Healthineers Faces a Pincer Movement: Tariff Headwinds and AI Costs Collide Ahead of Q2 Results

Siemens Healthineers stock near 52-week low as investors await clarity on €500M tariff impact and AI spending vs. margins, with analysts divided on outlook.

The next few days will be pivotal for Siemens Healthineers. As the medical technology group prepares to release its quarterly figures, investors are demanding clarity on two fronts: how the company plans to absorb a looming €500 million tariff hit in fiscal 2026, and whether its heavy spending on artificial intelligence can coexist with stable margins.

The stock, currently trading at €34.94, has lost more than a fifth of its value since the start of the year and sits just 3% above its 52-week low of €33.80. That leaves it roughly 30% below its 12-month peak — a slide that has split the analyst community sharply.

A Divided Analyst Camp

Barclays remains one of the more bullish voices on the Street. Analyst Hassan Al-Wakeel reaffirmed a €55 price target and an Overweight rating this week, pointing to a growth driver he believes the market is underestimating: PSMA-PET imaging for prostate cancer. His conviction was strengthened after a meeting with the management of Eckert & Ziegler, a radiation technology firm that plans to double its production capacity for Ga68 generators — components essential for certain PSMA-PET scans.

Al-Wakeel sees this as a clear signal for Siemens Healthineers. The potential is substantial: Germany currently operates around 150 PET scanners, whereas the US would have between 600 and 700 at comparable penetration rates. Demand is also rising in cardiology and neurology, broadening the opportunity beyond oncology.

Not everyone shares that optimism. Goldman Sachs recently slashed its price target from €52 to €45, maintaining a Neutral stance. Analyst Richard Felton cited fading momentum, margin pressure, and intensifying competition as reasons for caution. JP Morgan, meanwhile, sticks with Overweight and a €61.30 target, sitting at the more optimistic end of the spectrum.

The Tariff Cloud and Margin Squeeze

The Overweight rating from Barclays comes against a difficult backdrop. For fiscal 2026, Siemens Healthineers has flagged a potential negative tariff impact of up to €500 million. That figure hangs over the stock like a storm cloud, and Barclays also expects profitability to decline due to a tough prior-year comparison, adverse currency movements, and weakness in China.

A glimpse at US rival GE Healthcare offers a cautionary tale. GE beat revenue expectations on the back of imaging growth, but rising costs ate into its margins. Barclays sees similar dynamics playing out at both Philips and Siemens Healthineers.

AI: The Double-Edged Sword

The company is also wrestling with the cost of innovation. A recent Harvard study tested OpenAI's "o1-preview" model and found it could solve text-based diagnostic puzzles more accurately than human experts in some cases. While real patient interaction remains firmly in the hands of doctors, the technology is pushing aggressively into clinical workflows.

For Siemens Healthineers, which is investing heavily in AI for its imaging systems, this creates a classic dilemma. The industry is debating two scenarios: AI as a digital guardian angel that double-checks physician diagnoses, or as an assembly-line model that handles initial readings while doctors merely supervise. Either path requires significant upfront investment, and the market wants proof that spending won't crush margins.

What to Watch in the Q2 Numbers

The quarterly report, expected in the coming days, will provide the next concrete data point. Investors will be watching two core segments closely: imaging and laboratory diagnostics. Both need to demonstrate resilience.

Structural tailwinds are supportive — waiting times for doctor appointments are rising, and demand for efficient diagnostics continues to grow. But the question is whether the operational business can absorb the triple threat of tariffs, currency headwinds, and a sluggish Chinese market without forcing management to revise its full-year guidance downward.